"Adagene recently reported promising Phase 1b/2 trial data for its cancer drug ADG126, which has shown potential to double standard survival rates, supported by a $25 million investment from Sanofi. However, H.C. Wainwright has lowered the stock price target to $7 due to concerns over the clarity of the development path, reflecting a cautious sentiment in the market."